Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Total 13F shares
-
43,014,505
-
Share change
-
-4,452,673
-
Total reported value
-
$5,198,663,082
-
Put/Call ratio
-
119%
-
Price per share
-
$121.85
-
Number of holders
-
431
-
Value change
-
-$577,210,448
-
Number of buys
-
267
-
Number of sells
-
158
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q1 2021
As of 31 Mar 2021,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
431 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
43,014,505 shares.
The largest 10 holders included
ARK Investment Management LLC, Capital International Investors, Nikko Asset Management Americas, Inc., NEA Management Company, LLC, Versant Venture Management, LLC, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock Inc., TWO SIGMA INVESTMENTS, LP, WADDELL & REED FINANCIAL INC, and TWO SIGMA ADVISERS, LP.
This page lists
434
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.